MedTrace Logo

Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

NCT04206644 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-04-12

No results posted yet for this study

Summary

The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients

Conditions

Interventions

OTHER

biological analysis

biological analysis of the Concentration of CCL18

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Patrick JEGO · Rennes University Hospital

Eligibility

Min Age
18 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2023-01-13
Completion
2027-02-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04206644 on ClinicalTrials.gov